Clinical Trial Update: A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update reporting safety, tolerability, and pharmacokinetics of VRDN-003 in participants with Thyroid Eye Disease; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thyroid Eye Disease

Drugs mentioned

• VRDN-003

Snippet

Sponsor: Viridian Therapeutics, Inc. | Conditions: Thyroid Eye Disease | Phase 3 | Status: COMPLETED